Out Of The Ordinary But Nevertheless Possible Dolutegravir Strategies

The other large, randomized, controlled, de novo study that used SRL only in one study arm reported malignancies in 4�C9 patients in the various study groups at 1?year after transplantation [91]. In a pooled analysis of 2-year data of two pivotal phase III SRL trials and two phase II studies, Mathew et?al. [13] summarized that SRL immunotherapy may be beneficial in protecting renal transplant patients from cancer. The other SRL de novo trials were either too small or do not yet have a sufficiently lengthy follow-up to evaluate the effect on the development of malignancies [17,59,76,89,92]. http://www.selleckchem.com/products/z-vad-fmk.html Even in the large SYMPHONY study, investigators did not find a difference in the rate of malignancies between the CNI and mTOR inhibitor arms at the 1-year follow-up [10]. The strongest evidence that mTOR inhibitors truly may reduce the incidence of post-transplant malignancies comes from the largest conversion study so far [51]. In the CONVERT trial, 11.0% of the 273 patients on CsA developed a malignancy within 2?years after randomization, compared with only 3.8% of the 551 SRL-converted subjects (P? http://www.selleck.cn/products/s-gsk1349572.html 3?years on average. An evaluation of the incidence of EVL-associated http://www.selleckchem.com/products/ly2157299.html post-transplant malignancies is not possible because EVL was always dosed with CsA. In the 3-year analysis of the B201 and B251 trials, Lorber et?al. [69] and V��tko et?al. [89] found a malignancy rate of ?5%. The combined analysis of the 1-year data from the 2306 and 2307 trials showed a malignancy incidence of ?2%, which also was not differently distributed between groups [71]. In summary, the impact of EVL on the development of post-transplant malignancies remains unclear because there are no head-to-head comparisons of CsA with EVL. Another solid piece of evidence that mTOR inhibitors may reduce tumor growth comes from nontransplanted patients with renal cell cancer. Temsirolimus, a water-soluble derivative of SRL, is the first drug ever to have been shown to prolong survival of patients with metastatic renal cell carcinoma [93]. A substantial but varied percentage of discontinuations for adverse events have been observed among mTOR inhibitor-treated patients in nonrandomized (17%) [52] and randomized studies with either de novo use: 15.5% [57], 38% [7], and 7.8% [10]; or after conversion: 28% [52] and 12% (CONCEPT) [75]. The main adverse events reported were wound-healing complications [7], gastrointestinal [10,51] and mucocutaneous side effects [51,57], bone marrow suppression [17], disorders of the blood [52] and lymphatic systems, infection [10], hyperlipidemia [17], and proteinuria [10,52] (Table?2).